| (Values in U.S. Thousands) | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 | Dec, 2020 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -12,200 | -9,320 | -8,470 | -2,210 | -2,420 |
| Net Income Growth | -30.90% | -10.04% | -283.26% | +8.68% | unch |
Tharimmune Inc (THAR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Tharimmune Inc. is a biotechnology company. It involved in developing a portfolio of therapeutic candidates for rare immune, inflammatory and oncologic diseases. Tharimmune Inc., formerly known as Hillstream BioPharma Inc., is based in BRIDGEWATER, NJ.
Fiscal Year End Date: 12/31